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ABSTRACT
Infection with Toxoplasma gondii (Tg) in the central nervous system causes 
behavioural, personality changes and psychotic symptoms mimicking schizophrenia, a 
psychiatric illness with unknown aetiology. The aim of this study was to determine the 
seroprevalence, serointensity of Tg IgG, IgM antibodies and Tg DNA in patients with 
Schizophrenia and its relationship with demographic profile and clinical factors. This 
was a cross-sectional study examining the role of Tg in patients with Schizophrenia 
attending the Sg Buloh Hospital and University Malaya Medical Centre (UMMC) 
during a period from July 2010 to December 2012. A total of 156 subjects consisting 
of 57 patients with chronic Schizophrenia, 44 acute Schizophrenia and 55 healthy 
individuals participated in this study. The demographic profiles, risks and clinical 
factors were examined to determine the positivity and intensity of Tg IgG, IgM 
antibodies and Tg DNA. The seropositivity and serointensity of Tg antibodies were 
measured using Enzyme Linked Immunosorbent Assay (ELISA) while positivity and 
intensity Tg DNA were measured using Real Time PCR. The seropositivity of IgG 
antibody were significantly higher in all Schizophrenia, remission and acute 
Schizophrenia patients than control (p<0.001). The serointensity of IgG antibody were 
also significantly higher in all Schizophrenia, remission and acute Schizophrenia 
patients than control (p<0.05). The positivity of DNA Tg were also significantly 
higher in all Schizophrenia, remission and acute schizophrenia than control (p<0.05). 
The intensity of Tg DNA were also significantly higher in all Schizophrenia, 
remission and acute Schizophrenia patients than control (p<0.05). This study suggests 
that Tg has a significant role in Schizophrenia.
iv
ACKNOWLEDMENTS
Firstly, I wish to thank Allah for giving me the opportunity to embark on my Masters 
and for completing this long and challenging journey successfully. I would like to 
express my appreciation and gratitude to my research main supervisor, Professor Dr 
Osman bin Che Bakar for the endlessly supervision, guidance and suggestions and 
also co-supervisors, Professor Dr Ainsah binti Omar for the support, guidance and 
assistance towards completion of this research.
I wish to extend my appreciation to Associate Professor Dr Hatim bin Sulaiman, Head 
of Department of Psychiatric Daycare Cinic University Malaya Medical Centre 
(UMMC), Dr Zulkifli bin Ghaus, Head of Department of Mental and Psychiatric 
Clinic of Hospital Sungai Buloh, Head of Staff nurse at Blood Collection Centre 
(UMMC) and staffs in UMMC, psychiatrist and staffs in Sungai Buloh Hospital for 
their cooperation and continuous support.
Many thanks also to Dr Ikhsan bin Selamat, Public Health Specialist, for his statistical 
assistance, staffs and colleagues of Teknologi MARA, Sungai Buloh who had been 
very helpful to me throughout the period of the study.
I want to thank to Universiti Teknologi MARA for the financial support with 
Fundamental Research Grant Scheme (FRGS).
Finally, I also would like to thank my family and husband for their understanding and 
support throughout this research.
CHAPTER ONE 
INTRODUCTION
1.1 RESEARCH BACKGROUND
1.1.1 Schizophrenia
In 1890, Emil Kraeplin, a German psychiatrist first recognized and described
Schizophrenia as a group of illness characterized by catatonia and
hebephrenia/disorganization that begun during adolescence and invariably lead to
social deterioration. Kraeplin proposed that this illness was a brain disease, which he
named the disease as dementia praecox and carried a poor prognosis. Later, Eugene
Bleuler, a Swiss psychiatrist in 1911 worked on the conce.pt of dementia praecox and
further classified the symptoms of this illness based on a fundamental of 4A-s
(Ambivalence, Autism, inappropriate/flatness of Affect or looseness of Association).
Kurt Schneider in 1959 later identified more psychopathology and symptoms, which
included the positive symptoms namely delusions and hallucinations. He further
classified them into Schneiderian First Rank Symptoms of Schizophrenia. These
symptoms/psychopathology were later incorporated into International Classification
of Diseases (ICD) and Diagnostic and Statistical Manual (DSM) classifications of
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Schizophrenia.
Schizophrenia is a chronic major debilitating mental illness characterized by 
disturbances in effect, thought, emotion, mood and behaviour. It is associated with 
changes in personality, deterioration in function and intelligence, poor judgement and 
insight (Ainsah & Osman, 2013). According to World Health Organization (WHO), 
“Schizophrenia” is referred as a severe mental disorder, which is characterized by 
profound disruptions in thinking, affecting language, perception, and the sense of self. 
Schizophrenia can occur at any age from 7 to 70, but more prevalent in late adolescent 
or early adulthood and mostly in the age group of 13-35 years old. The prevalence of 
Schizophrenia is approximately 1% and affects more than 21 million people 
worldwide (WHO, 2014).
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